Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by hemi3tcon Jul 07, 2021 2:31pm
210 Views
Post# 33506315

RE:RE:RE:5 things to like about Ventripoint

RE:RE:RE:5 things to like about VentripointAnything Covid related was selling out like hotcakes or better than hotcakes, like toilet papaer.
Manufacturing for Ventilators went into overdrive and the VMS should have been selling well not stalled.     So something is not adding up  if the news from VPT is to be believed.



.Global evaluation of echocardiography in patients with COVID-19
 
European Heart Journal - Cardiovascular Imaging, jeaa178, https://doi.org/10.1093/ehjci/jeaa178, Published: 18 June 2020
 
Aims to describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography.
 
 
Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases,JAMA Cardiol. Published online July 27, 2020. doi:10.1001/jamacardio.2020.3551
 
COVID-19 and Heart Failure With Preserved Ejection Fraction
 
AMA. Published online September 30, 2020. doi:10.1001/jama.2020.17445
 
Reports an echocardiographic study of 100 patients with COVID-19 found the most common abnormalities were right ventricular dilation (39%)



woundedknee wrote: At the time of that story the Wuhan virus was just beginning its trek around the worls and VPT as well as many other companies were automatically stalled. So in my opinion, that is not a fair reference point. The question is, if not for the virus, would those sales and installations quotas been met. gl


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse